1、Peter CoombsMRC CMM Partnerships SummitLifeArcDiscoveryLate translationPost-academia,pre-venture capital,proof of conceptDesigning molecules/assaysNavigating developmentProtecting innovationMarket approvalEarly translationPre-and early clinical trialsClinical proof of conceptRegulatory submissionsBu
2、ilding cohortsDemonstrating safety and efficacyOur focus&goalsWe focus on rare diseases&Global HealthGoalsCollaborate across sectors and bordersDevelop treatments&diagnosticsCoordinate efforts to improve policies and regulationWe help promising scientific ideas reach the next phase of development th
3、rough investment,partnerships and expertise for health conditions that need it mostGlobal Health Global Health-Infection Translational ChallengeAt least 2 billion people globally are currently affected by infectious diseases,with disproportionate mortality and morbidity in low resource settingsOur p
4、otential for impact:Faster&sustainable innovation translationOptimized patient outcomesa reduction in mortality and morbidity from infectionsPrevent and control drug-resistant infections in highly impacted populationsASPIRECollaboration with ReAct Africa that aims to transform the use of antibiotics
5、 in hospitals in Zambia and KenyaLifeArc funding is supporting a surveillance and stewardship program aided by the development of innovative digital solutionsCrick Africa NetworkCollaboration with The Francis Crick Institute supporting Career Acceleration Fellowships in AfricaLifeArc will provide fu
6、nding,scientific mentorship and training in commercialisation and leadershipAfrica Drug Discovery AcceleratorCo-funding with the Gates Foundation Grand Challenges to African research institutes for 3-year drug discovery programs LifeArc provides funding,techni